Advertisement

Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Deborah Collyar: What's In It for Patients?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Advertisement

Advertisement




Oct
15
Today In Oncology
New AACI President-Elect Selected; Two Cancer Center Leaders Join Board
10-Year Incidence of Second Cancers in HPV Oropharyngeal Cancer
Individuals With Rare Cancers Present Distinct Diagnosis Patterns; Many Experience Treatment Delays
Combination Therapies for Diffuse Large B-Cell Lymphoma 5-Year Outcomes of POLARIX Trial
Chemotherapy-Free Regimen vs Standard Immunochemotherapy in Mantle Cell Lymphoma in Older Patients
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo